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Injury to the distal respiratory epithelium has been implicated as an underlying cause of idiopathic lung diseases. Mutations
that result in SP-C deﬁciencies are linked to a small subset of spontaneous and familial cases of interstitial lung disease (ILD)
and interstitial pulmonary ﬁbrosis (IPF). Gene-targeted mice that lack SP-C (Sftpc −/−) develop an irregular ILD-like disease
with age and are a model of the human SP-C related disease. In the current study, we investigated whether rapamycin could
ameliorate bleomycin-induced ﬁbrosis in the lungs of Sftpc −/− mice. Sftpc +/+ and −/− mice were exposed to bleomycin with
either preventative administration of rapamycin or therapeutic administration beginning eight days after the bleomycin injury.
Rapamycin-treatment increased weight loss and decreased survival of bleomycin-treated Sftpc +/+ and Sftpc −/− mice. Rapamycin
did not reduce the ﬁbrotic disease in the prophylactic or rescue experiments of either genotype of mice. Further, rapamycin
treatment augmented airway resistance and reduced lung compliance of bleomycin-treated Sftpc −/− mice. Rapamycin treatment
was associated with an increased expression of proﬁbrotic Th2 cytokines and reduced expression of INF-γ. These ﬁndings indicate
that novel therapeutics will be required to treat individuals with SP-C deﬁcient ILD/IPF.
1.Introduction
Pulmonary ﬁbrosis is a progressive and often fatal con-
dition characterized pathologically by mesenchymal cell
proliferation in the lung, expansion of the extracellular
matrix, and extensive remodeling of the lung parenchyma
[1]. Lung ﬁbrosis occurs in interstitial lung diseases and
idiopathic interstitial pneumonias, as part of several systemic
connective tissue diseases and childhood interstitial lung
disease syndromes, and in response to many types of
lung injury, including radiation and some chemotherapeutic
drugs. Idiopathic pulmonary ﬁbrosis (IPF) is perhaps the
most intractable form of lung ﬁbrogenesis where the molec-
ular origins are unclear. Recent evidence indicates that the
prevalence and mortality of IPF are growing in the U.S. and
elsewhere [2].
Currently, there are no approved medical antiﬁbrotic
therapies for pulmonary ﬁbrosis. Initial therapies focused
on aggressive anti-inﬂammatory treatment; however, this
approach has not improved loss of lung function or survival.
Pulmonary ﬁbrosis remains a signiﬁcant public health bur-
den with no proven therapies that prevent or reverse disease
progression. As pulmonary ﬁbrosis is likely heterogeneous in
molecular etiology, identiﬁcation of common downstream
pathways where signals converge may provide optimal thera-
peutic targets that will allow treatment of ﬁbrosis regardless
of the upstream initiating events.
Chronic exposures to inhaled particles, infections, and
genetic mutations or deﬁciencies that modify lung function
are responsible for persistent inﬂammation and ﬁbrotic lung
diseases. Alveolar type II epithelial cells produce and secrete
surfactant lipids and surfactant-associated proteins SP-A,2 Pulmonary Medicine
SP-B, SP-C, and SP-D that enhance alveolar compliance
and host defense [3]. Recent studies demonstrated a strong
associationbetweensurfactantproteinCgenemutationsand
familial idiopathic pulmonary ﬁbrosis [4]. SP-C is a small
34 amino acid hydrophobic, alpha-helical protein that is
selectively synthesized type II epithelial cells in the lung and
secreted into the airspace along with other surfactant lipids.
Genetic mutations that can cause misfolding or amyloid
ﬁbril formation of SP-C are often associated with interstitial
lung disease [5, 6]. In particular, L188Q mutation in SP-C
has been shown to associate with human lung disease and
foundcytotoxicwhenoverexpressedinmouselungepithelial
cells [7]. SP-C-deﬁciencies are also associated with human
lung disease. SP-C deﬁcient mice (Sftpc −/−) also developed
heterogeneousinterstitiallungdiseasewithage[8].However,
molecular mechanisms or pathways that mediate pulmonary
inﬂammation and ﬁbrosis in SP-C deﬁcient mice remained
unidentiﬁed.
The mammalian target of rapamycin (mTOR) has been
shown to inﬂuence tissue ﬁbrosis and is considered a
potential control point for pharmacological intervention [9,
10]. In support, inhibition of mTOR with rapamycin has
been shown to prevent the initiation and propagation in a
mouse model of TGFα-driven pulmonary ﬁbrosis [11–14].
The antiﬁbrotic aﬀects of mTOR inhibition have recently
beenreportedinseveralratmodelsofchronickidneydisease,
including diabetic nephropathy, chronic glomerulosclerosis,
and tubulointerstitial ﬁbrosis [15–17]. In rat models of
established liver cirrhosis, rapamycin reduced ﬁbrosis and
attenuated disease progression [18]. Together, these studies
support rapamycin as a potential novel therapy in the
treatment of pulmonary ﬁbrosis. Recent recommendations
regarding minimal preclinical criteria to be applied before
embarking on clinical trials of novel agents in patients with
IPF includes demonstration of the antiﬁbrotic eﬀects of the
agent in at least two diﬀerent animal models of lung ﬁbrosis,
with drug being delivered during the postinﬂammatory,
ﬁbrogenic phase of lung injury [19]. In this study, we
evaluated if rapamycin was eﬀective in reducing bleomycin-
induced inﬂammation and pulmonary ﬁbrosis in the SP-
C deﬁcient mice that exhibit an increased response to
proﬁbrotic stimuli.
2. Methods
2.1. Animal Model. Sftpc −/− mice were generated by gene
targeting techniques. These mice lack SP-C and have been
previously described [8]. Sftpc −/− mice were backcrossed
onto the 129S6 background to produce a congenic Sftpc −/−
129S6 line of mice that develop lung pathology with age.
Mice were maintained in a pathogen-free barrier facility, and
sentinel mice were negative for bacterial and viral pathogens.
All animals were handled under aseptic conditions. Studies
were performed under animal use protocols approved by the
institutional animal care and use committee.
2.2. Administration of Bleomycin and Rapamycin. Stock
bleomycin (Teva Pahramceuticals, North Wales, PA) was
prepared by resuspension in sterile PBS (phosphate buﬀered
saline) at 5U/mL and stored at −80◦C. Stock was diluted at
time of treatment to 0.5U/mL and a single 100ul (0.05U)
delivered by oral aspiration to six-week-old mice that were
lightly anesthetized by inhalation of Isoﬂurane (Abbott
Laboratories). Rapamycin (LC Laboratories, Woburn, MA)
was prepared as a 30mg/mL stock in EtOH and diluted to
0.6mg/mL in 0.25% PEG400/0.25% Tween20. Rapamycin
wasadministeredbyintraperitoneal(IP)injectionof4mg/kg
of body weight. Rapamycin doses were selected based upon
previously eﬀective reduction of injury in experimental lung
ﬁbrosis [14]. Control animals were given IP injection of
equivalent volumes of the ethanol-detergent dilution vehicle
and/or a single oral aspiration of PBS for bleomycin-exposed
mice.
2.3. Rapamycin Treatment Strategies. Prevention studies
were performed to determine if rapamycin administration
prior to and throughout the bleomycin-induced ﬁbro-
sis would prevent or reduce the apparent injury. Daily
rapamycin or vehicle IP injections were started two days
prior to the single bleomycin exposure and maintained for
14 days following the bleomycin exposure. There were 10
Sftpc +/+ and −/− mice in each experimental treatment
group.
Rescuestudieswereconductedtodetermineifrapamycin
could reduce an evolving ﬁbrotic injury. Sftpc −/− mice
received a single 0.05U bleomycin aliquot by oral aspiration
on day 0 and daily rapamycin treatments were begun on
day 8 and ended on day 22 after bleomycin. The weights
of mice were monitored every two days during both the
prevention and rescue experiments. The saline + vehicle
and bleomycin + vehicle groups had 8 mice each, and the
bleomycin + rapamycin experimental group had 12 mice.
Mice were euthanized on day 22 with sodium pentobarbital
and lung tissues were collected for RNA, protein, and
histological analysis.
2.4. Quantiﬁcation of Bronchoalveolar Lavage-Associated
Inﬂammatory Cells. On day 17, mice were euthanized with
sodium pentobarbital (65mg/kg) and lungs were lavaged
sequentially with three 1mL aliquots of PBS, pooled, and
used to determine total cell counts and for cytospin prepara-
tions to determine diﬀerential cell counts. Cells were isolated
from the bronchoalveolar lavage ﬂuid (BALF) by centrifu-
gation at 1250rpm for 5 minutes, and the cell pellet were
r e s u s p e n d e di n1 m Lo fP B Sa n dc e l l sw e r ec o u n t e du s i n g
hemocytometer. Cell counts were obtained on 5 animals per
experimental group. Cell free supernatants were frozen with
Rocheproteaseinhibitors,andlater,BALFtotalproteinlevels
were determined using the Pierce bicinchoninic acid (BCA)
protein assay kit (Thermo Scientiﬁc, Rockford, IL).
2.5. Lung Histology. Lungs of Sftpc +/+ and −/− mice were
collected at day 22 (experimental endpoint) and divided for
biochemical and histological analysis. The left lobe was
isolated by ligation with surgical suture, removed, and snap
frozen for protein and RNA isolation and gene expressionPulmonary Medicine 3
analysis. The right lobes were inﬂation ﬁxed with 10%
buﬀered formalin and removed. Each lobe was bisected,
processed, and embedded in paraﬃn. 5-micron tissue sec-
tions were cut and stained with hematoxylin and eosin and
with Mason’s trichrome stain to visualize morphology and
determine the extent and local sites of increased collagen
deposition. The lobar airways were scored for the presence
or absence of goblet cells as an indication of airway
inﬂammation.
2.6. Lung Collagen Determination. Total soluble lung colla-
gen was measured using the Sircol collagen assay (Biocolor
Ltd, County Antrim, UK). One half of the left lobe from
each animal was homogenized in 5mL of 0.5M acetic
acid,1mgpepsin/10mg tissue and held overnight to solu-
bilize tissue. Commercial Sircol dye reagent was added to
tissue lysates (1mL/100ul lysate; 30 minutes) and mixtures
centrifugedat 12,000rpm for 12 minutes and the pellets
resuspended in 1mL of 0.5 NaOH and the optical density
measured.
2.7. Lung Mechanics. Lung mechanics were determined on
anesthetizedmiceusingacomputerizedFlexiVentApparatus
(SCIREQ Montreal Canada) as previously describe [14].
Brieﬂy, mice were anesthetized with a ketamine-xylazine
mixture,tracheostomized,andventilatedwithatidalvolume
of 8mL/kg at a rate of 150 breaths/minute and 2cm of H2O
positive end expiatory pressure (PEEP) as computerized by
the SCIREQ system, thereby permitting analysis of dynamic
lung compliance and airway resistance. The calibration
procedure removed impedance from the instrument and
tracheal tube.
2.8. RNA Preparation and Cytokine Gene Expression by Real-
Time PCR. QuantitativePCRanalysiswasusedtodetermine
cytokine gene expression. The lung tissues (∼20–30mg)
from PBS-treated and bleomycin-treated mice were stored
at −80◦C. Total RNA was extracted using the SV total RNA
isolation system from Promega (Madison, WI) and reverse-
transcribed using iScript cDNA synthesis kit (BIO-RAD,
Hercules, CA). Real-time polymerase chain reaction (RT-
PCR) performed on StepOnePlus Real-Time PCR system
(Applied Biosystems, Foster City, CA). Relative quantities of
mRNA for several genes were determined using SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA). In
this method, mRNAs for each sample were normalized to
hypoxanthine guanine phosphoribosyl transferase (HPRT)
mRNA amounts and then expressed as a relative increase or
decrease compared with vehicle-treated control mice. Real-
time primers used in this study are listed in Table 1.
2.9. Statistics. Data was analyzed with Prism (Version 5;
GraphPad). Diﬀerences between groups were considered
statistically signiﬁcant for P values less than .05, obtained
with a one-way ANOVA. Tukey’s multiple comparison
posttest was used to compare diﬀerent experimental groups.
3. Results
The importance of inﬂammation in the initiation of experi-
mentally induced ﬁbrosis is unclear and may vary depending
upon the speciﬁc proﬁbrotic challenge. Early bleomycin
response includes a signiﬁcant inﬂammatory component
prior to ﬁbrosis. The Sftpc −/− mice have an intrinsic
pulmonary inﬂammation, increased response to inﬂamma-
tory challenge and a delayed or impaired resolution to
bleomycin induced ﬁbrosis. Thus, the Sftpc −/− mice are
a useful model to assess candidate anti-inﬂammatory and
antiﬁbrotic therapeutics such as rapamycin. Here, the eﬀects
of rapamycin were ﬁrst tested in a preventative scheme prior
to and during the developing ﬁbrotic injury followed by
studies to discern potential postinjury rescue.
3.1. Early Treatment with Rapamycin Did Not Confer Protec-
tion from Bleomycin-Induced Lung Damage in SP-C Deﬁcient
Mice. Sftpc +/+ and Sftpc −/− mice were pretreated two days
prior to the bleomycin insult to maximize steady state drug
levels and thus the potential to block or reduce the early
bleomycin related inﬂammation (Figure 1(a)). The overall
heath and survival was monitored and individual weights
within each treatment group were measured. Control ani-
mals (rapamycin without bleomycin) remained healthy with
a modest weight gain. Both bleomycin only and bleomycin
plus rapamycin treated groups had rapid weight loss that
began on day four after bleomycin treatment (Figures 1(b)
and 1(c)). The bleomycin plus rapamycin-treated mice had
a greater weight loss than the bleomycin only challenged
group both in Sftpc +/+ and −/− mice. This unexpected
result was supported by increased mortality beginning day
16postbleomycinexposureinthebleomycinplusrapamycin
treated mice (data not shown).
Analysis of the BALF from the study groups were used
to determine if rapamycin altered the cellular inﬂammatory
response or decreased vascular leak by determining total
protein content. Total cell counts in the BALF were increased
inthebleomycintreatedSftpc +/+ andSftpc −/− micerelative
to control mice. In wild-type mice, bleomycin-induced
cellular inﬁltration is attenuated with rapamycin treatment,
but BALF protein levels were unchanged (Figure 1(b)).
However, rapamycin treatment has no signiﬁcant eﬀect on
BALF cells or protein levels in Sftpc −/− mice (Figure 1(c)).
Rapamycin treatment also has no signiﬁcant eﬀect on
tissue inﬂammation in both wild-type and Sftpc −/− mice
(Figure 1(d)). We measured tissue collagen using sircoll
assay to quantify rapamycin driven responses on pulmonary
ﬁbrosis. Bleomycin treatment has signiﬁcantly increased
lung collagen in Sftpc +/+ (Figure 1(b), right panel) and
Sftpc −/− mice (Figure 1(c), right panel). We observed a
modest decrease in lung collagen with rapamycin treatment
in Sftpc −/− mice; however, the decrease observed was not
statistically signiﬁcant.
The cellular component of BALF from control Sftpc +/+
mice was predominantly macrophages with normal mor-
phology while the BALF of control Sftpc −/− mice con-
tained enlarged macrophages and a small percentage of
neutrophils (Figures 2(a) and 2(b), top panels). The enlarged4 Pulmonary Medicine
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Figure 1: Early rapamycin treatment does not reduce bleomycin-induced acute lung injury in Sftpc +/+ or −/− mice. (a) Diagram of
experimental protocol for prevention study to test aﬀects of rapamycin on bleomycin-induced lung ﬁbrosis. Sftpc +/+ and −/− mice were
treated with daily rapamycin or vehicle 2 days prior to administration of intratracheal bleomycin or saline. (b) Changes in body weights,
total BALF cells, BALF protein, and total lung collagen are shown fro Sftpc +/+ mice. (c) Changes in body weights, total BALF cells, BALF
protein, and total lung collagen are shown for Sftpc −/− mice. (d) H&E stained representative lung histology is shown, all panels 40x
magniﬁcation.Pulmonary Medicine 5
Table 1: Real-time primers used in the study. The fold change was obtained by normalizing the gene expression number to those of HPRT,
then comparing the samples to the PBS-treated or control mice.
Gene Forward Reverse
HPRT GCCCTTGACTATAATGAGTACTTCAGG TTCAACTTGCGCTCATCTTAGG
IL-13 CCTCTGACCCTTAAGGAGCTTAT CGTTGCACAGGGGAGTCTT
IL-4 ACGAGGTCACAGGAGAAGGGA AGCCCTACAGACGAGCTCACTC
IFN-γ AGAGCCAGATTATCTCTTTCTACCTCAG CCTTTTTCGCCTTGCTGTTG
Table 2: Goblet cell positive large airways (secondary bronchi).
Treatment Sftpc +/+ Sftpc −/−
PBS + rapamycin 0/23 0/16
Bleomycin + vehicle 3/25 (12) 6/19 (32)
Bleomycin + rapamycin 0/10 4/13 (31)
( ) % positive airways.
macrophages and low-level neutrophil presence in BALF of
Sftpc −/− mice has been previously reported [8]. Rapamycin
treatment alone did not alter the morphology of lavage
cells from Sftpc +/+ mice (top left panel, Figure 2(b)).
Enlarged foamy macrophages and increased numbers of
neutrophil were detected in the BALF of bleomycin exposed
Sftpc +/+ and −/− mice. The rapamycin treatment did not
alter/improve the bleomycin-induced foamy macrophage
morphology in either genotype (Figure 2(b), lower pan-
els). There was an incremental increase in neutrophils
in the BALF of Sftpc +/+ mice. The percentage of neu-
trophils was further increased in the BALF of Sftpc −/−
mice (bleomycin exposed and rapamycin treated) and the
macrophagemorphologycontainedhighlyvacuolatedfoamy
macrophages that clustered as aggregates. Airway inﬂamma-
tion was observed by the morphological presence of goblet
cells in the airway epithelia of bleomycin and bleomycin-
exposed rapamycin treated mice. The extent of goblet cell
transformation was more extensive in bleomycin-treated
Sftpc −/− mice, and the goblet cell transformation was not
reducedbyrapamycintreatment(Table 2).Collectively,these
results indicated that the presence of rapamycin prior to
inﬂammation did not provide protection to bleomycin-
induced lung ﬁbrosis.
3.2. Rapamycin Treatment after Bleomycin Challenge Does
Not Alter Pulmonary Inﬂammation and Fibrosis in SP-C-
Deﬁcient Mice. A second set of studies were focused on the
eﬀects of rapamycin delivered during the postinﬂammatory,
ﬁbrogenic phase of lung injury in Sftpc −/− mice. These
experiments were performed in Sftpc −/− mice to evaluate
any protective recovery of bleomycin-induced lung damage
with rapamycin treatment.
Sftpc −/− mice were given a single saline or bleomycin
challenge and daily rapamycin (4mg/kg body weight)
administered 8 days after bleomycin when inﬂammation was
established(Figure 3(a)).Similartothepreventionstudy,the
controlrapamycinonlytreatedmicehadasteadyweightgain
and no mortality. In contrast, the bleomycin and bleomycin
plus rapamycin groups had steady decline in body weights
beginning 2 days after rapamycin treatment (Figure 3(b)).
Weightlosswasmoresevereinthebleomycinplusrapamycin
group similar to the trends in the early rapamycin pre-
vention experiments. Survival was again reduced in the
bleomycin-exposed mice (data not shown). H&E stained
lung sections were analyzed to evaluate tissue inﬂammation
due to bleomycin and rapamycin treatments. Increased tis-
sue inﬂammation was observed during bleomycin-induced
lung injury, and this increase remained unchanged with
rapamycin treatment (Figure 3(c)). Cellular inﬁltrates were
mixed including foci of polymorphonuclear cells, lympho-
cytes, and enlarged foamy macrophages (macrophages visi-
ble in Figure 3(c)). These results indicated that the cellular
inﬂammation that occurs early in bleomycin injury was not
diminished by delay in the rapamycin treatment. Images are
representative of 3–5 mice per treatment group. Collectively,
the above results suggest that rapamycin treatment has no
protective eﬀects on bleomycin-induced lung inﬂammation.
Moreover, we observe a delay in weight gain upon rapamycin
treatments during bleomycin challenge in Sftpc −/− mice.
Pulmonary ﬁbrosis was evaluated by light microscopy of
sections stained with Mason’s trichrome stain to visualize
altered morphology and the potential increase and distri-
bution of tissue collagen within the lungs. Morphology of
control mice appeared normal with thin bands of collagen
(blue strands) associated in the typical perivascular and
peribronchiolar pattern (Figures 4(a) and 4(b)). In contrast,
the lungs of bleomycin and the bleomycin plus rapamycin-
treated Sftpc −/− mice had extensive disruption of lung
architecture and obstruction of alveolar spaces (Figures 4(c)
and 4(d)). Extended webs of collagen positive staining areas
were present in an irregular pattern throughout the lobe.
Fibroblastic-like cellular arrays were seen in the trichrome
positive regions at higher magniﬁcation (Figures 4(d) and
4(f)). The histological ﬁndings were consistent with the
biochemical quantiﬁcation of total lung collagen. Soluble
collagen was measured in lung homogenates of the left lungs
for each experimental group. Collagen was increased in the
lungs of bleomycin plus vehicle mice relative to collagen
in the lungs of the saline control group of Sftpc −/− mice
(Figure 4(g)). Total lung collagen remained increased in
the bleomycin exposed-rapamycin treated Sftpc −/− mice
indicating that there was no antiﬁbrotic eﬀects of rapamycin
(n = 8–12 mice per group).
3.3. Rapamycin Treatment Alters Lung Mechanics in Bleo-
mycin-Treated SP-C-Deﬁcient Mice. Airway resistance was
increased in the lungs of bleomycin-treated Sftpc −/− mice6 Pulmonary Medicine
Bleomycin +
rapamycin
Bleomycin +
vehicle
Saline +
rapamycin
−20
0
20
40
60
80
100
T
o
t
a
l
c
e
l
l
s
p
e
r
ﬁ
e
l
d
(
%
)
Sftpc+/+ Macs
Sftpc−/− Macs
Sftpc+/+ Neut
Sftpc−/− Neut
(a)
B
l
e
o
m
y
c
i
n
+
r
a
p
a
m
y
c
i
n
B
l
e
o
m
y
c
i
n
+
v
e
h
i
c
l
e
S
a
l
i
n
e
+
r
a
p
a
m
y
c
i
n
Sftpc+/+ Sftpc−/−
(b)
Figure 2: Diﬀerential cell counts and morphology of inﬂammatory cells found in BALF. (a) Macrophages and neutrophils were counted and
expressed as a percentage of the total cells counted from cytospin preparations. (b) Representative images of cytospin preparations of BALF
cells are shown. Arrowheads identify enlarged foamy macrophages while the arrow indicates a neutrophil for comparison of inﬂammatory
changes among the experimental groups. All images were photographed at 60x magniﬁcation.
and further increased in the bleomycin plus rapamycin
group of Sftpc −/− mice (Figure 5(a)). Airway compliance
was reduced in the bleomycin treated mice relative to
saline- and vehicle-treated group. Airway compliance was
further reduced in the bleomycin plus rapamycin group
(Figure 5(b)). Together, these ﬁndings indicate that the
rapamycin treatment resulted in worsening lung function
in bleomycin-treated Sftpc −/− mice (n = 8–12 mice per
group). However, rapamycin-treated alone has no eﬀect on
airway resistance and lung compliance. Th2 cytokines IL-4
and IL-13 have been implicated in altered lung function in
various pulmonary disease models and in promoting airway
goblet cell hyperplasia [20, 21]. To test whether the sustained
injury and poor mechanics were associated with altered
Th2 cytokine levels, we measured expression of select Th2
cytokine genes in the lungs from the control and bleomycin
+/− rapamycin treated Sftpc −/− mice. IL-4 and IL13 gene
expression was increased in the bleomycin treated mice rela-
tivetothevehicleongroup(Figure 6).Weobservesigniﬁcant
increases in IL-4 and IL-13 from the lungs of the bleomycin
plus rapamycin mice relative to the bleomycin-only-treated
group. Furthermore, we also observed attenuation of antiﬁ-
brotic IFN-γ levels in rapamycin and bleomycin treatment
compared bleomycin-treated group. These ﬁndings are con-
sistent with rapamycin potentiating airway remodeling in
bleomycin-treated Sftpc −/− mice (n = 4 mice per group).
4. Discussion
Using an Sftpc −/− mouse model, the present study
demonstrates that administration of rapamycin did not
prevent the initiation or the progression of bleomycin-
driven pulmonary ﬁbrosis. Rapamycin treatment exacer-
bated bleomycin-associated alterations in lung mechanics
and altered Th2 cytokine gene expression in Sftpc −/− mice.
4 . 1 .A l t e r e dS P - CE x p r e s s i o nU n d e r l i e saG e n e t i c a l l yD e ﬁ n e d
Lesion to Investigate a Discrete Form of IPF. Some patients
with idiopathic forms of pulmonary ﬁbrosis have a familial
pattern of recurrent disease suggesting a genetic component
to these cases. The familial forms are of considerable
interest regarding the diverse origins attributed to IPF,
as they have the potential to reveal a speciﬁc gene defect
that generates a previously idiopathic disease [5]. The
human SP-C gene (SFTPC)i so n eo fv e r yf e wg e n e sw h o s e
dysfunction is directly linked to the induction of pulmonary
ﬁbrosis. Individuals with a speciﬁc SFTPC mutation can
have extremely variable case histories that range from
severe acute infant or early childhood onset of ILD, to
progressive ILD or pulmonary ﬁbrosis emerging throughout
adulthood [4, 7, 22]. The majority of SFTPC mutations
cluster in the carboxy-terminal region of the proform of
the SP-C protein, altering the proprotein structure and
impairing processing. The decreased processing of pro-SP-C
also reduces the amount of available mature SP-C in the
airspace. There are additional reports of SP-C deﬁcient IPF
where there is no mutation in the SFTPC sequence and
no detectable aberrant pro-SP-C to induce injury [22, 23].
These ﬁndings infer that the ﬁbrosis results directly from
the absence of SP-C, but the phenotype is complex, where
individual severity and ontogeny may be aﬀected by multiple
factors.Pulmonary Medicine 7
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Figure 3:Laterapamycintreatmentdoesnotreducebleomycin-inducedweightlossinSftpc −/− mice.(a)Diagramofexperimentalprotocol
forrescuestudiestotestaﬀectsofrapamycinonbleomycininducedlungﬁbrosis.Sftpc −/− miceweretreatedwithdailyrapamycinorvehicle
beginning 8 days following administration of intratracheal bleomycin or saline. (b) Body weights in mice receiving bleomycin decreased
compared to saline-treated mice. (c) H&E images of mouse lungs 22 days after bleomycin administration. Images in panel (c) are 40x
magniﬁcation.
4.2. The SP-C-Deﬁcient Mice Provide a Genetic Model of the
Human SP-C-Driven ILD/IPF. To further understand the
role of the SP-C protein in human disease, we previously
generated SP-C knockout (Sftpc −/−) mice. The pulmonary
phenotype in Sftpc −/− mice is complex with features similar
to human pathology. On the 129S6 genetic background,
Sftpc −/− mice exhibited progressive cellular inﬂammation
and interstitial like disease with extensive remodeling,
airspace loss and patchy ﬁbrosis in a subset of the older
Sftpc −/− mice [8].
The 129S6 Sftpc −/− mice also demonstrated an intrinsic
increased cellular inﬂammation including elevated base-
line neutrophils and a population of activated alveolar
macrophages [8]. Similar ﬁndings were seen with the control
Sftpc −/− mice in this study that had slightly elevated
neutrophilcountsandfoamymacrophagesintheBALFprior
to any bleomycin challenge. When the 129S6 Sftpc −/− mice
were challenged by bacterial or viral infection, mice had
increased injury that included robust unremitting inﬂam-
mation relative to Sftpc +/+ mice [24]. Viral and bacterial
infections have also been associated with acute respiratory
illness in individuals with SFTPC mutations implicating SP-
C in innate lung defense [4, 7, 22]. The mechanism whereby
SP-C deﬁciency predisposes the lung to inﬂammation is
unknown and remains under investigation. SP-C has been
shown to bind to LPS and block TLR signaling in vitro,
suggesting SP-C regulates proinﬂammatory responses to
acute injury.
4.3. The Sftpc −/− Mice Are More Sensitive to Bleomycin-
Induced Inﬂammation. We previously demonstrated that8 Pulmonary Medicine
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Figure 4: Late rapamycin treatment does not reduce bleomycin-
induced pulmonary ﬁbrosis in Sftpc −/− mice. Sftpc −/− mice
were treated with daily rapamycin or vehicle beginning 8 days
following administration of intratracheal bleomycin or saline. (a)–
(f) Mason’s trichrome staining demonstrates increased lung matrix
deposition in bleomycin-administered mice (c)–(f) compared to
saline-treated mice (a, b). (a, c, e) (10x magniﬁcation), (b, d, f)
(40x magniﬁcation). (g) Total lung collagen was increased in mice
receiving bleomycin compared to saline-treated mice. There were
no diﬀerences in total lung collagen in bleomycin mice treated with
rapamycin or vehicle.
Sftpc −/− mice on a Swiss/Black (S/B) mixed genetic
background do not display any intrinsic lung pathology yet
weremoresusceptibletolunginjuryfollowingchallengewith
bleomycin [25]. The S/B Sftpc −/− m i c eh a da ni n c r e a s e d
and sustained neutrophil inﬂux relative to S/B Sftpc +/+ mice
administered bleomycin. S/B Sftpc −/− mice also demon-
strated increased collagen deposition with delayed resolution
compared to Sftpc +/+ mice. In the current, study inﬂam-
mation was sustained in the lungs of 129S6 Sftpc −/− mice
compared to 129S6 Sftpc +/+ mice with bleomycin treatment
until the termination at day 22. On the 129S6 back-
ground, the Sftpc −/− mice eventually develop ILD-like lung
pathology [8]. Airway epithelial inﬂammation was increased
by bleomycin treatment supporting the concept that SP-
C confers protection to the airway epithelium (Table 2).
Airway inﬂammation quantiﬁed by the presence of goblet
cells was increased in 129S6 Sftpc −/− mice relative to
Sftpc +/+ mice, and the goblet cell hyperplasia was not
reduced by rapamycin treatment. While SP-C is expressed
in the alveolar epithelium, SP-C is detected in tracheal
aspirates of infants and thus a component of airway lining
ﬂuid. In addition, the cellular inﬂammation in the BALF
of Sftpc −/− mice was not altered by rapamycin treatment.
Taken together, these ﬁndings are consistent with SP-C func-
tioning to limit alveolar and airway epithelial inﬂammation.
4.4. Rapamycin Has No Eﬀect on Bleomycin-Induced Tissue
Fibrosis. Rapamycin binds to an intracellular cytoplasmic
receptor, the FK506-binding protein-12 [11, 15]. This
complex interacts and inhibits mTOR function leading
to cell-cycle arrest in the G1 phase. Rapamycin derivates
sirolimus and everolimus are utilized clinically primarily as
an immunosuppressive agent following organ transplanta-
tion, but has also been investigated as an antineoplastic
agent and as adjunctive therapy in systemic diseases [15–
18]. In pulmonary ﬁbrosis models, there is limited data
on activation of mTOR and the eﬀectiveness of rapamycin
treatment. Rapamycin prevented ﬁbrosis in transgenic mice
overexpressing transforming growth factor-alpha (TGFα)a s
wellaspreventedprogressionofﬁbrosiswhenrapamycinwas
administered after extensive ﬁbrosis had already developed.
Similar to the TGFα model, the rapamycin analog SDZ
RAD prevented bleomycin-induced pulmonary ﬁbrosis in
rats although it was unclear whether changes in lung inﬂam-
mation may have contributed to these improvements [26].
Notably, in this model, histological evaluation failed to show
a signiﬁcant diﬀerence in apparent ﬁbrosis between animals
receivingbleomycinaloneandthosereceivingbleomycinand
SDZ RAD. In another study by Mehrad et al. using C57BL/6,
mice also reported antiﬁbrotic eﬀects of rapamycin [27].
However, both of these studies used a diﬀerent species or
strain of mice and also low doses of rapamycin. Moreover,
the 129 strain of mice are known to be sensitive to bleomycin
induced injury. In gene microarray experiments following
bleomycin treatment, the 129 strain of mice were shown
to have a distinct expression proﬁle that overlapped with
the expression proﬁle of bleomycin challenged C57/BL6
mice [28]. It is also possible that partial inhibition of mTORPulmonary Medicine 9
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Figure 5: Late rapamycin treatment alters bleomycin-induced changes in the lung mechanics of Sftpc −/− mice. Sftpc −/− mice were treated
with daily rapamycin or vehicle beginning 8 days following administration of intratracheal bleomycin or saline. (a) Airway resistance was
higher in mice receiving both bleomycin and rapamycin. (b) Compliance was decreased in mice receiving bleomycin compared to saline-
treated mice and rapamycin-treated mice demonstrated signiﬁcantly worse compliance than mice treated with vehicle.
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Figure 6: Late rapamycin treatment increases bleomycin-induced increases in IL-4 and IL-13 in Sftpc −/− mice. Sftpc −/− mice were treated
with daily rapamycin or vehicle beginning 8 days following administration of intratracheal bleomycin or saline. IL-4, IL-13 and interferon
gamma were measured by RT-PCR.10 Pulmonary Medicine
signaling with a low dose of rapamycin may be protective
against bleomycin-induced ﬁbrosis. Therefore, future studies
will be needed to evaluate internal and external factors that
maycontributetomTORpathwayactivationandantiﬁbrotic
doses of rapamycin. These studies will be useful to address
diﬀerences in ﬁbrosis associated with a speciﬁc genetic back-
ground of mice and doses of rapamycin in bleomycin-driven
ﬁbrosis. To date, there are no published clinical trials testing
the eﬃcacy of mTOR inhibition in patients with pulmonary
ﬁbrosis; however, there is one case report describing partial
remission of IPF in a patient treated with rapamycin [29].
As rapamycin has both immunomodulatory and antiﬁ-
brotic properties, we hypothesized rapamycin would be an
eﬀective intervention to amend the ﬁbrosis and exacer-
bated inﬂammation in the Sftpc −/− bleomycin model. In
the current study, rapamycin was ineﬀective in reducing
inﬂammation and ﬁbrosis when administered either as a
preventative pretreatment regimen or delayed until 8 days
following the onset of bleomycin injury in Sftpc −/− mice.
However, rapamycin was eﬀective in reducing inﬂammatory
cells in BALF of 129S6 Sftpc +/+ mice. The lungs of Sftpc −/−
mice with or without daily rapamycin treatments retained
collagen rich tissue as well as irregular mixed inﬂammatory
cell inﬁltrates. Rapamycin-treated Sftpc −/− mice demon-
strated persistent weight loss, and both airway resistance
and compliance were further compromised. The goblet cell
hyperplasia in bleomycin exposed Sftpc −/− mice both with
and without rapamycin may in part account for the impaired
lung mechanics.
4.5. Rapamycin Alters Cytokine Gene Expression in the
Lungs of Bleomycin-Exposed Sftpc −/− Mice. At day 22 after
bleomycin, both diﬀuse and discrete regional concentra-
tions of polymorphonuclear leukocytes, lymphocytes, and
enlarged foamy macrophages were observed. The ongo-
ing mixed cellular alveolitis in the treated and untreated
Sftpc −/− mice was not reduced by rapamycin and may
in part be due to sustained cytokine activation. Bleomycin
stimulated expression of IL-4 and IL13 relative to the control
mice.Expressionwasfurtherincreasedintherapamycinplus
bleomycin group of Sftpc −/− mice. Elevated Th2 cytokines
might be responsible for observed increases in airway
remodeling due to rapamycin treatment during bleomycin-
induced lung damage.
Diﬀerential eﬀects of rapamycin on cytokines levels are
also observed in other models of tissue damage and repair.
In particular, rapamycin has been shown to polarize the Th2
type cellular response in vitro that was dependent upon IL-4
[30]. IL-13 contributes to induction of bleomycin mediated
ﬁbrosis in mice [31]. A mechanism by which rapamycin
exerts the hypothesized Th2 bias in SP-C deﬁcient mice
is unknown but is consistent with the cellular inﬂux and
airway inﬂammation reported herein. In addition bacterial
and viral challenges of Sftpc −/− mice have resulted in an
increased goblet cell hyperplasia that is a Th2-dependent
process [24, 32]. Future studies will be needed to determine
the phenotype of the inﬂammatory cells recruited into the
lungs of injured Sftpc −/− mice.
4.6. Rapamycin Associated Pulmonary Toxicity in Humans.
Our ﬁndings of deteriorated lung function in rapamycin-
treated Sftpc −/− mice may provide insight into the known
and potentially devastating toxicity observed in patients.
Pulmonary toxicity from mTOR inhibitors such as sirolimus
and everolimus has been reported in up to 15% of patients
with a wide spectrum of disease severity, ranging from
subclinical to fulminant respiratory failure [33, 34]. Several
distinct types of pulmonary damage have been recognized,
including lymphocytic interstitial pneumonitis, lymphocytic
alveolitis, bronchiolitis obliterans with organizing pneumo-
nia, pulmonary alveolar proteinosis, alveolar hemorrhage,
focal pulmonary ﬁbrosis, or a combination of these entities
[33–36] .T r e a t m e n ti n c l u d e sd o s er e d u c t i o no rw i t h d r a w a l
of medication and corticosteroids are administered in severe
cases [34, 36]. Clinical improvement with resolution of
pulmonary ﬁndings is usually rapid although protracted
resolution is reported in severe cases of pneumonitis [36].
The pathogenic mechanism of pulmonary toxicity asso-
ciated with mTOR inhibition is not well understood.
Both a direct, dose-dependent toxicity and an autoimmune
response or delayed hypersensitivity reaction triggered by
exposure to mTOR inhibitors with or without a cryptic pul-
monary antigen have been postulated as possible underlying
pathogenetic mechanisms [34]. mTOR inhibition has also
been hypothesized to hamper cellular repair in alveolar cells
by the inhibition of growth factor-driven signal transduction
response, thereby exacerbating epithelial injury [35, 37].
Potential clinical relevance is that patients with acute
lung injury from a variety of causes such as infection or
ventilation often produce less or transiently shut oﬀ SP-C
production [38]. Our data demonstrates that in the absence
of SP-C, rapamycin treatment following acute lung injury
may exacerbate the immune response by shifting to a Th2
response.
In summary, to date, each deﬁned genetic modiﬁer of
acute lung injury and ﬁbrosis occurs through functionally
unrelated cellular events. For instance, mutations in the
telomerase genes alter either the RNA required to primer
telomere repeat replication or the enzyme that extends the
repeats. Mutations in the pulmonary collectin, SP-A has
been associated with familial ﬁbrosis and susceptibility to
infection. Hermansky Pudlak gene mutations alter vesicle
traﬃc proteins and are linked to sporadic inﬂammation and
lung ﬁbrosis with age. Thus, it may be that each mutation-
cellular deﬁciency that eventually elicits inﬂammation and
ﬁbrosiswillrequireindividualizedinhibitordesign.Andonly
a very small subset of idiopathic lung disease the focus on
SFTPC-relatedIPFwillaidindeﬁningcellularandmolecular
alterations that provide insights to other undeﬁned forms of
IPF and their inhibitors.
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